Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus
Abstract We hypothesize that serum irisin can have additional discriminative potency for heart failure (HF) in individuals with type 2 diabetes mellitus (T2DM). The study group comprised 226 consecutive T2DM patients (153 patients with any HF phenotypes and 30 patients without HF) aged 41 to 65 year...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2022-11-01
|
| Series: | Molecular Biomedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43556-022-00096-x |
| _version_ | 1798018422055895040 |
|---|---|
| author | Alexander A. Berezin Ivan M. Fushtey Sergii V. Pavlov Alexander E. Berezin |
| author_facet | Alexander A. Berezin Ivan M. Fushtey Sergii V. Pavlov Alexander E. Berezin |
| author_sort | Alexander A. Berezin |
| collection | DOAJ |
| description | Abstract We hypothesize that serum irisin can have additional discriminative potency for heart failure (HF) in individuals with type 2 diabetes mellitus (T2DM). The study group comprised 226 consecutive T2DM patients (153 patients with any HF phenotypes and 30 patients without HF) aged 41 to 65 years. The plasma levels N-terminal brain natriuretic pro-peptide (NT-proBNP) and irisin were detected by ELISA at the baseline of the study. We found that the most appropriate cut-off value of irisin (HF versus non-HF) were 10.4 ng/mL (area under curve [AUC] = 0.96, sensitivity = 81.0%, specificity = 88.0%; P = 0.0001). Cutoff point of NT-proBNP that distinguished patients with HF and without it was 750 pmol/L (AUC = 0.78; sensitivity = 72.7%, specificity 76.5%, p = 0.0001). Using multivariate comparative analysis we established that concentrations of irisin < 10.4 ng/mL (odds ration [OR] = 1.30; P = 0.001) and NT-proBNP > 750 pmol/mL (OR = 1.17; P = 0.042), left atrial volume index (LAVI) > 34 mL/m2 (OR = 1.06; P = 0.042) independently predicted HF. Irisin being added to NT-proBNP improved predictive modality for HF, whereas combination of NT-proBNP and LAVI > 34 mL/m2 did not. In conclusion, we established that irisin had independent predicted potency for HF in patients with established T2DM. |
| first_indexed | 2024-04-11T16:23:55Z |
| format | Article |
| id | doaj.art-e44af645d9944412ba6eb35d995327f7 |
| institution | Directory Open Access Journal |
| issn | 2662-8651 |
| language | English |
| last_indexed | 2024-04-11T16:23:55Z |
| publishDate | 2022-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Molecular Biomedicine |
| spelling | doaj.art-e44af645d9944412ba6eb35d995327f72022-12-22T04:14:14ZengSpringerMolecular Biomedicine2662-86512022-11-013111010.1186/s43556-022-00096-xPredictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitusAlexander A. Berezin0Ivan M. Fushtey1Sergii V. Pavlov2Alexander E. Berezin3Zaporozhye Medical Academy of Postgraduate EducationDepartment of Therapy and Endocrinology, Zaporozhye Medical Academy of Postgraduate EducationDepartment Clinical and Laboratory Diagnostics, Zaporozhye State Medical UniversityTherapeutic Unit, Internal Medicine Department, Zaporozhye State Medical UniversityAbstract We hypothesize that serum irisin can have additional discriminative potency for heart failure (HF) in individuals with type 2 diabetes mellitus (T2DM). The study group comprised 226 consecutive T2DM patients (153 patients with any HF phenotypes and 30 patients without HF) aged 41 to 65 years. The plasma levels N-terminal brain natriuretic pro-peptide (NT-proBNP) and irisin were detected by ELISA at the baseline of the study. We found that the most appropriate cut-off value of irisin (HF versus non-HF) were 10.4 ng/mL (area under curve [AUC] = 0.96, sensitivity = 81.0%, specificity = 88.0%; P = 0.0001). Cutoff point of NT-proBNP that distinguished patients with HF and without it was 750 pmol/L (AUC = 0.78; sensitivity = 72.7%, specificity 76.5%, p = 0.0001). Using multivariate comparative analysis we established that concentrations of irisin < 10.4 ng/mL (odds ration [OR] = 1.30; P = 0.001) and NT-proBNP > 750 pmol/mL (OR = 1.17; P = 0.042), left atrial volume index (LAVI) > 34 mL/m2 (OR = 1.06; P = 0.042) independently predicted HF. Irisin being added to NT-proBNP improved predictive modality for HF, whereas combination of NT-proBNP and LAVI > 34 mL/m2 did not. In conclusion, we established that irisin had independent predicted potency for HF in patients with established T2DM.https://doi.org/10.1186/s43556-022-00096-xType 2 diabetes mellitusHeart failureIrisinNatriuretic peptidesPredictive model |
| spellingShingle | Alexander A. Berezin Ivan M. Fushtey Sergii V. Pavlov Alexander E. Berezin Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus Molecular Biomedicine Type 2 diabetes mellitus Heart failure Irisin Natriuretic peptides Predictive model |
| title | Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| title_full | Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| title_fullStr | Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| title_full_unstemmed | Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| title_short | Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| title_sort | predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus |
| topic | Type 2 diabetes mellitus Heart failure Irisin Natriuretic peptides Predictive model |
| url | https://doi.org/10.1186/s43556-022-00096-x |
| work_keys_str_mv | AT alexanderaberezin predictivevalueofserumirisinforchronicheartfailureinpatientswithtype2diabetesmellitus AT ivanmfushtey predictivevalueofserumirisinforchronicheartfailureinpatientswithtype2diabetesmellitus AT sergiivpavlov predictivevalueofserumirisinforchronicheartfailureinpatientswithtype2diabetesmellitus AT alexandereberezin predictivevalueofserumirisinforchronicheartfailureinpatientswithtype2diabetesmellitus |